High prevalence but no current clinical relevance of methyldibromo glutaronitrile since its ban in Turkey in 2015.
Esen ÖzkayaÖmer MangırPublished in: Contact dermatitis (2024)
The ban effectively reduced MDBGN-induced ACD in Turkey, yet the prevalence of positive patch test reactions remains high, likely due to past exposures or other undisclosed sources. We suggest continued testing of MDBGN in the EBS in Turkey.